Trustiva Tablet
| SKU | 1088 |
|---|---|
| Generic For | Viraday |
| Strength | 300 mg, 200mg & 600 mg |
| Manufacturer | HETERO LABS. LTD |
| Active Ingredient | Tenofovir Disoproxil Fumarate (300 mg), Emtricitabine (200 mg), and Efavirenz (600 mg) |
| Pack Size | Qty | Price Per Pill or Unit | Price | Cart | |
|---|---|---|---|---|---|
| 30 Capsules | US$ 1.83 | US$ 55.0076%US$ 225.23 | |||
|
|||||
| 60 Capsules | US$ 1.67 | US$ 100.0078%US$ 450.46 | |||
|
|||||
| 90 Tablet/s | US$ 1.67 | US$ 150.0078%US$ 675.69 | |||
|
|||||
Trustiva Tablet – Affordable Viraday Alternative
Trustiva Tablet is a prescription medicine and should be used under the supervision of a health care specialist. It comprises of three components, namely Efavirenz, Tenofovir, and Emtricitabine. All the three active ingredients help to control your HIV infection, thereby improving your quality of life. The medicine can be prescribed alone or in combination with other medications. Never share your combination drug with others, and take it for the indication prescribed.
The information contained here in this document is not intended to cover all possible uses, precautions, drug interactions, directions, adverse events, or warnings. If you have any doubt about the medication that you are taking, check with your physician.
What is Trustiva used for?
Trustiva is not only used to treat HIV in adults, but also lowers the risk of getting HIV complications liek new infection, cancer, etc.
How does Trustiva work?
Trustiva works by blocking the activity of a viral enzyme, inhibiting the replication of HIV cells. In this way, it lowers the growth and decreases the amount of HIV in the body.
What medications interact with Trustiva?
Do not use Trustiva with the following drugs:
- Tenofovir
- Atazanavir
- Amprenavir
- Lopinavir
- Ritonavir
- Saquinavir
- Didanosine
- Raltegravir
- Boceprevir
- Telaprevir
- Anticoagulants like warfarin
- Anticonvulsants like carbamazepine and phenytoin
- Antidepressants like bupropion and sertraline
- Oral contraceptives
- Calcium channel blockers like diltiazem used to treat high blood pressure
- Simvastatin for lowering cholesterol
- Herbal preparation containing St. john’s wort
- Cisapride, for reflux
- Triazolam for anxiety and sedation
When should Trustiva not be taken?
Avoid taking Trustiva tablets:
- If you are pregnant or breastfeeding
- If you are suffering from hepatitis B infection
- If you have renal or hepatic insufficiency
- If you are allergic to any of the ingredients present in the preparation
How should Trustiva be taken?
Take one Trustiva tablet on an empty stomach. Swallow it with a glass full of water. Try to take it one hour before or two hours after a meal. Preferred taking it at bedtime.
How long should you take Trustiva?
Continue taking medicine regularly for as long as your physician recommends. Your physician will monitor your condition on a regular basis.
Missed dose of Trustiva
Take your missed dose of Trustiva medicine as soon as possible, except when it is close to the time for your regular next one. If in case, the time to take the next dose is close, skip the missed dose and go back to your normal dosing schedule. You are not supposed to take two doses at the same time. If you find problem remembering your dose, please ask your physician for a solution.
How should Trustiva be stored?
Keep all the medicines out of the reach of children and away from pets. The medicine must be stored in a cool, dry place. Keep it away from the reach and sight of children.
What are the side effects of Trustiva?
Here is a list of side effects that may occur during the treatment with Trustiva. However, the list is not a comprehensive one. The following side effects are possible, but do not always occur.
- Itching
- Nausea
- Weakness
- Hyperglycemia
- Abnormal dreams
- Tiredness
Consult your physician if you experience any of the above-mentioned side effects, especially if they trouble you. You may experience side effects other than these, some may be rare, but serious.
What is Trustiva used for?
Trustiva contains tenofovir disoproxil fumarate (TDF) — a nucleotide reverse transcriptase inhibitor (NtRTI) used in combination antiretroviral therapy (cART) for HIV-1 infection, and as part of dual therapy for chronic hepatitis B. As part of HIV cART, Trustiva/TDF is typically combined with emtricitabine (FTC) or lamivudine as the NRTI backbone, plus a third agent. TDF has been the cornerstone NRTI backbone in first-line HIV therapy globally since the mid-2000s due to its potency, once-daily dosing, and activity against both HIV and HBV.
How does tenofovir disoproxil fumarate work against HIV?
Tenofovir DF is a prodrug that is converted intracellularly to tenofovir diphosphate (active form) — a competitive inhibitor of HIV reverse transcriptase. It competes with natural deoxyadenosine 5'-triphosphate for incorporation into viral DNA, causing chain termination. The long intracellular half-life of tenofovir diphosphate (12–50 hours) enables once-daily dosing. Unlike nucleoside analogues (which require three phosphorylation steps), TDF enters cells as a monophosphate — bypassing the rate-limiting first phosphorylation step and achieving higher intracellular concentrations efficiently.
How should Trustiva (TDF) be taken?
Trustiva is taken once daily with or without food. Food increases bioavailability slightly but the difference is not clinically significant. Consistent daily dosing is essential — HIV adherence below 95% risks viral rebound and resistance. Take at the same time each day with or without a meal. TDF is almost always used as part of a fixed-dose combination (e.g. with emtricitabine as Truvada, or in other single-tablet regimens) for convenience. When used as a separate tablet, confirm the complete three-drug (or more) regimen is being taken simultaneously.
What are the renal risks of Trustiva (tenofovir DF) and how are they monitored?
TDF causes proximal renal tubular toxicity (Fanconi syndrome) in a subset of patients — reduced tubular reabsorption of phosphate, glucose, amino acids, urate, and bicarbonate. Risk factors: pre-existing renal impairment, low body weight, older age, concurrent nephrotoxic drugs, and boosted protease inhibitors (increase TDF plasma levels). Monitor: eGFR at baseline, 3 months, then 6-monthly; urine phosphate/creatinine ratio (phosphaturia precedes eGFR decline); serum phosphate. If eGFR <50 mL/min, switch to tenofovir alafenamide (TAF) — has equivalent antiviral activity with significantly reduced renal and bone toxicity.
Is Trustiva (TDF) safe in patients with hepatitis B co-infection?
TDF is the preferred agent for HIV/HBV co-infected patients — it is active against both viruses. TDF 300mg daily provides potent HBV DNA suppression with a high genetic resistance barrier (no TDF-resistant HBV strains have been documented in clinical practice). When TDF is the NRTI backbone for HIV treatment in co-infected patients, it simultaneously treats HBV without requiring additional hepatitis B-specific antivirals. Caution: if TDF is ever discontinued (for renal reasons), HBV reactivation can cause severe hepatitis — ensure alternative HBV-active therapy is initiated before stopping TDF in co-infected patients.
What drug interactions are important with Trustiva (TDF)?
Boosted protease inhibitors (lopinavir/ritonavir, atazanavir/ritonavir, darunavir/ritonavir) significantly increase TDF plasma levels by inhibiting renal tubular TDF excretion — increase nephrotoxicity risk; monitor renal function closely. Didanosine (ddI) plasma levels increase with TDF — increased ddI toxicity; combination not recommended. NSAIDs and other nephrotoxic agents potentiate renal toxicity. Rifampicin reduces TDF levels modestly — not usually clinically significant. Antacids containing polyvalent cations may reduce TDF absorption — separate by 2 hours.
How does Trustiva (TDF) compare to tenofovir alafenamide (TAF)?
Trustiva contains tenofovir disoproxil fumarate (TDF), which is used in HIV treatment to reduce the amount of virus in the body. Tenofovir alafenamide (TAF) is a newer form of tenofovir that delivers the medicine more efficiently into cells. Both are effective for HIV control, but TAF usually works at a lower dose and may cause less strain on the kidneys and bones compared to TDF. However, TDF is widely used, effective, and often more affordable. The choice depends on overall health, kidney function, and treatment goals.
Is Trustiva (TDF) equivalent to Viread?
Yes. Trustiva and branded Viread both contain tenofovir disoproxil fumarate 300mg in bioequivalent formulations. Trustiva is the generic alternative providing the same HIV and hepatitis B antiviral efficacy as branded Viread at significantly lower cost — critical for resource-limited HIV treatment programmes globally.
Can I order Trustiva from PremiumRxDrugs for international delivery?
Yes. PremiumRxDrugs.com ships Trustiva to the USA, UK, Australia, and many other countries. Our genuine manufacturer-verified antiretrovirals, competitive pricing, and free worldwide shipping on qualifying orders make us a reliable international source for tenofovir-based HIV and HBV therapy.
What side effects does Trustiva (TDF) cause?
Common: nausea, vomiting, flatulence, and headache — generally mild and resolve within weeks. Renal: proximal tubulopathy (see above), decreased bone mineral density (monitor with DXA scan at baseline and yearly in high-risk patients). Fanconi syndrome (severe tubular dysfunction): hypophosphataemia, glycosuria, proteinuria, aminoaciduria — rare but requires immediate switch to alternative. Lactic acidosis: nucleotide class warning — rare with TDF. Hepatic flare: if TDF stopped in HBV co-infected patient. Skin hyperpigmentation rarely reported. Monitor renal function consistently to detect early toxicity before irreversible renal damage occurs.
What bone density effects does Trustiva (TDF) have and how are they managed?
TDF reduces bone mineral density (BMD) by 2–6% compared to TAF-based regimens over 48 weeks. The mechanism involves TDF's renal phosphate wasting (hypophosphataemia reduces bone mineralisation) and direct effects on osteoblast/osteoclast balance. At-risk groups: post-menopausal women, patients with existing osteoporosis, heavy smokers, those on prolonged corticosteroids. Management: calcium and vitamin D supplementation (all TDF-treated patients should be on calcium 1,000mg + vitamin D 800IU daily), baseline DXA scan repeated every 2–3 years, switching to TAF-based regimen when renal or bone concerns arise, and bisphosphonate therapy for significant osteoporosis.
Login
Sign Up
Login
Sign Up